Previous use of Statins and Atrial Electrical Remodeling in Patients with Cryptogenic Stroke

Cardiovasc Hematol Disord Drug Targets. 2017;17(3):212-215. doi: 10.2174/1871529X18666180111115646.

Abstract

Background: In the general population the leading cause of cardioembolic stroke is atrial fibrillation (AF). A silent AF is also the possible cause of many cryptogenic strokes. P wave dispersion (PWD), a predictor of AF, has been proposed as a marker of silent AF occurrence in these strokes. PWD correlates with high-sensitive C-reactive protein levels reflecting the role of inflammation in promoting a slowed and inhomogeneous atrial conduction. Statins have a multitude of additional effects beyond lipid lowering, in particular anti-inflammatory effects that may influence atrial conduction.

Objective: The aim of this study was to evaluate the effects of previous statin use on PWD in patients with cryptogenic stroke, in order to highlight a possible role for statins in preventing atrial conduction alterations that predispose to AF.

Method: We enrolled 131 patients (67 males, 64 females; mean age 69±13 years) with cryptogenic stroke. All patients underwent neuroimaging examination, arterial ultrasound examination, echocardiography and ECG. PWD was measured in all subjects.

Results: Patients previously treated with statins (n: 34) had lower PWD and P index values in comparison with no-statin group (41.7±12.2 vs 48.7±15.2 ms, p=0.01, and 14.2±3.7 vs 16.5±5.3 ms, p=0.02, respectively).

Conclusions: Our results show lower PWD values in cryptogenic stroke patients previously treated with statins. These findings provide support to the hypothesis that statins may play a role in modulating atrial electrophysiological and structural properties, preventing the occurrence of a slowed and heterogeneous atrial conduction and finally, reducing the occurrence of AF.

Keywords: ECG; Ischemic stroke; P wave dispersion; atrial fibrillation; cryptogenic stroke; inflammation.; statins.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnostic imaging
  • Atrial Fibrillation / prevention & control
  • Atrial Remodeling / drug effects*
  • Echocardiography
  • Electrocardiography
  • Female
  • Heart Conduction System
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Neuroimaging
  • Risk Factors
  • Stroke / diagnostic imaging
  • Stroke / prevention & control*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors